Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adipic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 5/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL27476208 | 0.97 | TSHR (0.75) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Adipic Acid SCHEMBL28221050 | 0.97 | LMNA (0.69) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Azelaic Acid SCHEMBL29124519 | 0.94 | TSHR (0.71) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Azelaic Acid SCHEMBL29124511 | 0.94 | TSHR (0.71) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Glutarate SCHEMBL540985 | 0.93 | SLC22A6 (0.73) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Adipic Acid SCHEMBL27700353 | 0.91 | LMNA (0.61) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Adipic Acid SCHEMBL28253795 | 0.88 | LMNA (0.65) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Sulfuric Acid SCHEMBL10485865 | 0.87 | TSHR (0.60) | LMNATSHRNFKB1PMP22SLC22A6 | |
| Hexanoate SCHEMBL28607461 | 0.87 | AKR1B1 (0.80) | LMNATSHRSLC22A6GPR84FFAR1 | |
| Succinic Acid SCHEMBL285597 | 0.86 | LMNA (0.69) | LMNATSHRNFKB1PMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117904688-A | Treatment process method for anodic oxidation dyeing of aluminum alloy | 丽岛新能源(安徽)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11896697-B2 | Composition for keratin fibers | L'OREAL (FR) | 2024-02-13 | — | — | US | disclosed |
| EP-4308093-A1 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING AMITRIPTYLINE AND AN ALKALINE AQUEOUS PHASE | Algotherapeutix (FR) | 2024-01-24 | — | — | EP | disclosed |
| US-20230103462-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PHANTOM LIMB PAIN | ALGOTHERAPEUTIX (FR) | 2023-04-06 | — | — | US | disclosed |
| US-20230103300-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF CORONAVIRUS-INDUCED NEUROPATHIC PAIN | ALGOTHERAPEUTIX (FR) | 2023-04-06 | — | — | US | disclosed |
| EP-4159196-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST L AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN FROM THE PHANTOM LIMB | Algotherapeutix (FR) | 2023-04-05 | — | — | EP | disclosed |
| EP-4159195-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN INDUCED BY A CORONAVIRUS | Algotherapeutix (FR) | 2023-04-05 | — | — | EP | disclosed |
| EP-4106726-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AN AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINE | Algotherapeutix (FR) | 2022-12-28 | — | — | EP | disclosed |
| US-20220387594-A1 | USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE | ALGOTHERAPEUTIX (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4098249-A1 | USE OF AMITRIPTYLINE AND/OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS AS A PRESERVATIVE AGENT | Algotherapeutix (FR) | 2022-12-07 | — | — | EP | disclosed |
| WO-2010029267-A1 | COSMETIC COMPOSITION CONTAINING QUATERNARY AMMONIUM ESTERS AND THICKENING POLYMERS, AND USE FOR HAIR CONDITIONING | L'OREAL (FR) | 2010-03-18 | — | — | WO | disclosed |
| EP-1992329-A1 | Dyeing composition comprising an aminopyrazolopyridine oxidation base and a specific associative polymer | L'Oréal (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1404288-B1 | COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND | OREAL (FR) | 2008-10-29 | — | — | EP | disclosed |
| EP-1340485-B1 | Aerosol foam composition containing a combination of a cationic vinylpyrrolidone polymer and a nonionic cellulosic compound and its use in cosmetics | OREAL (FR) | 2008-02-13 | — | — | EP | disclosed |
| EP-1404288-A2 | COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND | L'OREAL (FR) | 2004-04-07 | — | — | EP | disclosed |
| EP-1340485-A2 | Aerosol foam composition containg a combination of a vinylpyrrolidone cationic polymer and a cellulosic compound and its use in cosmetics | L'OREAL (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002051372-A2 | COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A AMINO PYRAZOLE AND A CELLULOSE COMPOUND | L'OREAL (FR) | 2002-07-04 | — | — | WO | disclosed |
| US-4066078-A | Disposable electrode | JOHNSON & JOHNSON (US) | 1978-01-03 | — | — | US | disclosed |
| US-4005251-A | SULFATION WITH ALKALI ACETYL SULFATE, ESTERIFICATION | JOHNSON & JOHNSON (US) | 1977-01-25 | — | — | US | disclosed |
| US-3939836-A | Water dispersible nonwoven fabric | JOHNSON & JOHNSON (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896697-B2 | Composition for keratin fibers | KRT18, PRKCZ, PRKCH | LMNA 2738/4885TSHR 4415/4885NFKB1 3094/4885 |
| US-20230103462-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF NEUROPATHIC PHANTOM LIMB PAIN | PMP22, GAP43, SUCLG1 | LMNA 2601/4885TSHR 4792/4885NFKB1 3036/4885 |
| US-20220387594-A1 | USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVE | TPH2, TPH1, SLC6A2 | LMNA 217/4885TSHR 3356/4885NFKB1 2491/4885 |
| US-20230103300-A1 | TOPICAL PHARMACEUTICAL COMPOSITION IN GEL FORM COMPRISING AT LEAST AMITRIPTYLINE FOR USE IN THE TREATMENT OF CORONAVIRUS-INDUCED NEUROPATHIC PAIN | GAP43, ACHE, ACE2 | LMNA 2519/4885TSHR 4861/4885NFKB1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.